LOQTORZI 240mg concentrate for solution for infusion medication leaflet

L01FF13 • toripalimab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors

Toripalimab is a monoclonal antibody used as cancer immunotherapy. It is a PD-1 inhibitor and is used mainly in adults with recurrent locally advanced or metastatic nasopharyngeal carcinoma; in some settings it is given with cisplatin and gemcitabine, and in others as a single medicine after platinum-based treatment.

By blocking the PD-1 receptor, toripalimab reduces one of the ways a tumour can switch off immune cells. This can allow T cells to become more active against cancer cells. It is not suitable for every patient, and the decision depends on cancer type, stage, previous treatments and general health.

Toripalimab is given by intravenous infusion in an oncology centre at intervals set by the doctor. Blood counts, liver tests, kidney function and hormone gland function are monitored during treatment. Tell your doctor if you have an autoimmune disease, transplant history, active infection, are pregnant or plan to become pregnant.

Common side effects may include tiredness, nausea, vomiting, reduced appetite, constipation or diarrhea, rash, fever, cough and muscle or joint pain. Immune reactions can affect the lungs, bowel, liver, kidneys, skin or thyroid. Seek urgent advice for shortness of breath, persistent fever, severe diarrhea, yellow skin or eyes, or confusion.